Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 12/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | PDE4A | P27815 | 2/20 | 0.60 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.60 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.60 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etamiphyllin SCHEMBL1651150 | 0.97 | ADORA2B (0.63) | ADORA2BLMNAMAPTPDE4APDE4B | |
| SCHEMBL683551 | 0.92 | ADORA2B (0.70) | ADORA2BLMNAMAPTPDE4APDE4B | |
| SCHEMBL6741317 | 0.91 | ADORA2B (0.71) | ADORA2BLMNAMAPTPDE4APDE4B | |
| SCHEMBL683897 | 0.90 | ADORA2B (0.71) | ADORA2BLMNAMAPTPDE4APDE4B | |
| Dimethazan SCHEMBL49056 | 0.87 | PDE4A (0.73) | ADORA2BLMNAMAPTPDE4APDE4B | |
| SCHEMBL11381846 | 0.87 | ADORA2B (0.64) | ADORA2BLMNAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL16120984 | 0.86 | ADORA2B (0.81) | ADORA2BLMNAMAPTALDH1A1SMN1; SMN2 | |
| Etamiphyllin SCHEMBL28142820 | 0.85 | LMNA (0.66) | ADORA2BLMNAMAPTPDE4APDE4B | |
| SCHEMBL8443037 | 0.84 | ADORA2B (0.77) | ADORA2BLMNAMAPTPDE4APDE4B | |
| SCHEMBL684274 | 0.83 | ADORA2B (0.67) | ADORA2BLMNAMAPTPDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 721 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119955725-A | Method for inducing pluripotent stem cells to transform into nerve cells by domestic dogs | 中国科学院昆明动物研究所 | 2025-05-09 | — | — | CN | claimed |
| CN-119893121-A | Pulse camera video reconstruction method based on time multi-resolution and fine granularity attention | 中国科学院大学 | 2025-04-25 | — | — | CN | claimed |
| CN-119514499-A | Text generation method and system based on model editing and knowledge fusion | 山西大学 | 2025-02-25 | — | — | CN | claimed |
| US-20250017878-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | CHRONIC AIRWAY THERAPEUTICS LTD (AU) | 2025-01-16 | — | — | US | claimed |
| WO-2024189434-A1 | USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2024-09-19 | — | — | WO | claimed |
| CN-118185865-A | TFAM conditional knockout cell line, myocardial cell, construction method and application thereof | 湖北大学 | 2024-06-14 | — | — | CN | claimed |
| CN-117987351-A | Method for improving production efficiency of buffalo living egg-taking embryo by co-culture of autologous cells | 广西壮族自治区水牛研究所 | 2024-05-07 | — | — | CN | claimed |
| EP-4304717-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | Chronic Airway Therapeutics Limited (AU) | 2024-01-17 | — | — | EP | claimed |
| CN-111549091-B | Method for testing activation and degranulation of basophils | 核工业总医院 | 2023-11-17 | — | — | CN | claimed |
| WO-2023051796-A1 | PRODUCTION SYSTEM AND METHOD FOR PRODUCING NANOPARTICLES | 上海弼领生物技术有限公司 | 2023-04-06 | — | — | WO | claimed |
| EP-0680479-B1 | METHOD FOR PREPARING BAMIFYLLINE AND ETAMIPHYLLINE | NYCOMED CHRISTIAENS NV SA (BE) | 1999-03-17 | — | — | EP | claimed |
| US-5739331-A | PREPARING BAMIFYLLINE AND ETAMIPHYLLINE | S.A. NYCOMED CHRISTIAENS N.V. (BE) | 1998-04-14 | — | — | US | claimed |
| EP-0480934-B1 | A SLIMMING PHARMACEUTICAL COMPOSITION | NYCOMED DAK AS (DK) | 1994-06-29 | — | — | EP | claimed |
| EP-0270305-B1 | SPHEROIDS | Euroceltique S.A. (LU) | 1993-01-20 | — | — | EP | claimed |
| EP-0480934-A1 | A SLIMMING PHARMACEUTICAL COMPOSITION. | DAK LAB AS (DK) | 1992-04-22 | — | — | EP | claimed |
| US-5091189-A | Tablet contains 3-alkylxanthine, hydrophilic or hydrophobic polymers, and wax from the group consists of polyalkylene glycol | EUROCELTIQUE S.A. (LU) | 1992-02-25 | — | — | US | claimed |
| WO-1991000730-A1 | A SLIMMING PHARMACEUTICAL COMPOSITION | DAK-LABORATORIET A/S (DK) | 1991-01-24 | — | — | WO | claimed |
| US-4908111-A | Process for the preparation of 7-(2-diethylaminoethyl)-theophylline acetyl salicylate and use thereof | Laboratories Boi, S.A. (ES) | 1990-03-13 | — | — | US | claimed |
| US-4844910-A | CONTROLLED RELEASE OF THEOPHYLLINE DERIVATIVES | EUROCELTIQUE, S.A. (LU) | 1989-07-04 | — | — | US | claimed |
| EP-0270305-A2 | Spheroids | Euroceltique S.A. (LU) | 1988-06-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250017878-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | ARRB1, ADRB2, ADRB1 | ADORA2B 500/4885LMNA 2136/4885MAPT 1043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.